Markets:

Overview

News

Currencies

International

Treasuries

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

16.80 -0.11 (-0.65%)

Streaming Delayed Price Updated: 3:10 PM EDT, May 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday ↗

November 08, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Theravance Biopharma Earnings Preview ↗

August 04, 2023

Via Benzinga

Earnings Preview: Theravance Biopharma ↗

February 24, 2023

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗

May 11, 2023

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...

Via Benzinga

Earnings Scheduled For May 8, 2023 ↗

May 08, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff ↗

February 28, 2023

Via Benzinga

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review

February 27, 2023

From Irenic Capital Management, LP

Via Business Wire

Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings ↗

November 17, 2022

Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday.

Via Benzinga

A Preview Of Theravance Biopharma's Earnings ↗

November 04, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

Here's Why Theravance Biopharma Shares Are Moving ↗

September 19, 2022

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading higher by 2.78% to $10.35 Monday afternoon after the company authorized a $250 million capital return program. What Else?

Via Benzinga

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

Looking Into Theravance Biopharma's Return On Capital Employed ↗

August 24, 2022

According to data from Benzinga Pro, during Q2, Theravance Biopharma's (NASDAQ:TBPH) reported sales totaled $11.05 million. Despite a 68.43% increase in earnings, the company posted a loss of $8.19...

Via Benzinga

Theravance Biopharma's Earnings: A Preview ↗

August 03, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session ↗

July 14, 2022

Gainers Shineco, Inc. (NASDAQ: SISI) shares climbed 24.5% to $1.2201 on heavy volume.

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 14, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 14, 2022

We're diving into all the latest stock market news with a breakdown of the biggest pre-market stock movers for Thursday!

Via InvestorPlace

Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday's Pre-Market Session ↗

July 14, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 22.1% to $0.2050 in pre-market trading. Allena Pharmaceuticals disclosed a new meeting date and new record date for special meeting to approve...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 13, 2022

Gainers

Via Benzinga

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗

July 13, 2022

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022 ↗

May 23, 2022

Via Benzinga

Theravance Biopharma's Earnings Outlook ↗

May 04, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's ↗

April 05, 2022

Theravance Biopharma Inc (NASDAQ: TBPH)

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.